Forecasts project rare disease drugs will exceed $400B in 2032 revenues (~21% of prescriptions), reinforcing their role as a core growth engine despite policy and competitive volatility. IRA revisions ...
Rapid Micro Biosystems, Inc. sees strong FY25 revenue growth from Growth Direct placements, but losses persist. Click for ...
Merck & Co.’s landmark cancer drug is still the industry’s bestseller despite the rise of GLP-1s — and other topics on our ...
With a market cap of $16.6 billion, West Pharmaceutical Services, Inc. (WST) is a healthcare company that designs, manufactures, and sells containment and delivery systems for injectable drugs and ...
Total revenue of Junshi Biosciences was approximately RMB2,498 million in 2025, representing an increase of approximately 28% compared to 2024, which was mainly due to the increase in revenue from ...
3hon MSN
Health care roundup: Market talk
Find insight on EssilorLuxottica, the pharmaceutical industry and more in the latest Market Talks covering the Health Care sector.
Kamada (KMDA) posted FY25 growth, reaffirmed 2026 guidance, and launched a new dividend policy. Read here for a detailed investment analysis.
After losing significant ground to rival Eli Lilly in the GLP-1 space over the past two years, Novo Nordisk is defending the one arena it now dominates — oral therapeutics. But with Lilly preparing to ...
Compounding pharmacies are illegally selling GLP-1 drugs, and the FDA is determined to shut that pathway down.
FY 2025 net revenue of $272.1 million, flat to FY 2024, and Adjusted EBITDA of $16.1 million Q4 2025 net revenue of $72.0 million, flat to Q4 2024 and Adjusted EBITDA of $6.6 million Obagi Medical see ...
The US Food and Drug Administration has revoked an approval issued in March to India's Sun Pharma Advanced Research Company Ltd (SPARC) to launch a drug for seizures, citing manufacturing quality ...
C.H. Unnikrishnan US drug maker Abbott Laboratories, which invested at least Rs 25,600 crore ($4 billion) in India in the last five years including the acquisition of domestic drug formulation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results